Auro Laboratories Limited share price
BSE: AUROLAB
Key numbers
- Market cap
- ₹ 150 Cr
- Current price
- ₹ 241.00
- 52-week high / low
- ₹ 317 / 159
- Stock P/E
- 32.1
- Book value
- ₹ 74.4
- Dividend yield
- 0.00%
- ROCE
- 9.0%
- ROE
- 7.9%
- Debt to equity
- 1.37
- Sales growth (3 yrs)
- -16.2%
- Profit growth (3 yrs)
- 13.1%
- 1-year return
- 0.6%
About Auro Laboratories Limited
Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India and internationally. It offers antihistamine; muscle relaxant; diuretic; iron deficiency; anti-diabetic; anti-fungal, ulcer, malaria, and inflammatory; iodine supplement; analgesics; antacids; potassium and sodium iodide; and microcrystalline cellulose. The company also provides specialty chemicals comprising guanidine nitrate; dimethyl amine HCl; 2-ethoxy benzoic acid; and 3,4,5 - trimethoxy benzoic acid. In addition, it offers intermediates consisting of glibenclamde sulphonamide for use in API glibenclamide; cis-bramo benzoate and cls-tosylate that are used in API Ketoconazol; 3,4,5 - trimethoxy benzoic acid; 2-ethoxy benzoic acid for use in API sildenafil citrate; and 5-bromo phthalide that is used in API citalopram. It also exports products to Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain, and the United Kingdom. The company was incorporated in 1989 and is based in Mumbai, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 3 | 9 | 9 | 10 | 9 |
| Operating profit | 0 | 2 | 4 | 3 | 3 |
| Net profit | -0 | 1 | 2 | 1 | 1 |
| EPS (₹) | -0.17 | 1.15 | 3.13 | 1.56 | 1.68 |
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.